D`OXYVA® IS DELIVERING THE PARADIGM SHIFT IN HEALTH SCIENCE
THINK BEYOND DIFFERENT, WAY BEYOND DIFFERENT™
D`OXYVA is empowering each and every one of us to quickly take control of our health in about 4-8 weeks and also measure results with independent and affordable consumer and medical diagnostics. Consult your physician and interpret your results. If you are interested in the latest non-invasive transdermal (over the skin) technology on the market with years of side-effect free track record, learn more by reading through this website. Top academics around the world in various fields have been testing and recommending it for a variety of conditions and now it is available to you. Get your D`OXYVA today with a box of cartridge supplies and experience the benefits after just a 5-minute daily D`OXYVA sprayed gently on your thumb or healthy skin on any problematic area on your body. No electricity or harmful chemicals are required, just about an ounce of clean drinking water filled in D`OXYVA's Water Capsule to operate the device.
D`OXYVA (deoxyhemoglobin vasodilator) is the world's most used, studied, affordable, fastest, lowest risk, non-invasive medical gas-powered handheld transdermal delivery device. It is intended for significant improvements in tissue microcirculation with cellular oxygenation (Bohr & Haldane effect), which is being recognized in a rapidly growing number of published randomized clinical trials leading to a variety of significant outcomes fast. According to leading research, microcirculatory dysfunction may be the underlying cause of the most widespread chronic illnesses. D`OXYVA has a track record of zero adverse side effect reports and hundreds of thousands of successful applications validated and reproduced by prestigious institutions and researchers around the world since 2011.
ACTIVATE MICROCIRCULATION WITH A COMPREHENSIVE SOLUTION
UNPRECEDENTED RESULTS & ZERO ADVERSE SIDE EFFECT REPORTS
We recognize the body’s powerful ability to provide for its own healing and well-being, and recognize blood as the delivery system for that ability. With D`OXYVA, Circularity has put the theory that better circulation is the key to improved quality of life, alleviating, and ultimately effectively treating the underlying cause of many of today's most difficult health conditions to the test.
D`OXYVA is currently being investigated by leading researchers around the world for the treatment of microvascular disease, diabetic foot ulcers, pressure ulcers, peripheral vascular disease, post-operative aid in plastic surgery, chronic kidney disease, hypertension, multiple myeloma, Alzheimer's disease, and many others. We are delighted to hear users of our products reporting unmatched improvements in:
and vital signs in just 4-8 weeks with zero adverse events.
This is why we established Circularity Healthcare in early 2011 after years of research and development, which is now an emerging multinational leader in proprietary circulatory and non-invasive applications. Learn more about Circularity Healthcare.
D`OXYVA has demonstrated unmatched increases in blood circulation, cellular oxygenation, tissue perfusion in the microvessels, and neural signal activation according to randomized human clinical trials.
Based on years of user feedback, D`OXYVA has shown significant improvements in cardiovascular activity leading to much improved physical activity, which, as part of a healthy lifestyle, may help significantly reduce the risk of high blood pressure, hypertension, cholesterol and diabetes in just two or three months with an average use of 5 minutes a day and 5 times a week.
D`OXYVA is one of a kind and is becoming a standard setter in numerous fields and the first choice of doctors around the world for studying the treatment of the most difficult complications caused by chronic diseases such as diabetes, cardiovascular disease and various forms of cancer such as multiple myeloma. It is a highly affordable low risk, non-invasive, non-toxic, both adjunct and standalone solution for the forward-looking health facility and patient wanting to significantly reduce cost of treatment while increasing patient compliance and reducing readmission rates.
MEASURE D`OXYVA'S PERFORMANCE IN SECONDS, FEEL & SEE BENEFITS IN A COUPLE OF WEEKS
D`OXYVA is the only advanced microvascular solution that works effectively by bolstering the natural healing foundation of the body: microcirculation. Restrictions in this form of circulation impede the flow of antibodies, white blood cells and platelets, and rob the skin and body of oxygen.
Microcirculation dysfunction is increasingly regarded by the mainstream scientific health community as the underlying cause of the most widespread health complications for both the young and elderly.
Our technologies patented worldwide focus on significantly improving the microcirculatory and cardiovascular functions and providing unparalleled patient outcomes in quality of life and esthetic benefits with zero adverse side effects. Based on our in-depth global market research, we are confident that D`OXYVA is a simpler, faster, and more affordable health solution than any other therapy on the market today.
INDUSTRY-LEADING CLINICAL RESEARCH RESULTS
LEADING INSTITUTIONS & RESEARCHERS
D`OXYVA is Circularity's first trademarked and patented noninvasive transdermal delivery system, which is the latest breakthrough in the field of transdermal delivery and microcirculatory health, according to the latest randomized human clinical trials. It is named after the two underlying mechanisms of action studied to be related to its powerful solution; deoxyhemoglobin vasodilator.
D`OXYVA has been demonstrating numerous significant health benefits for years in record time and has been reviewed, studied, and used at institutions around the world such as Penn State University, Florida State University, Valley Presbyterian Hospital, Hospital Kuala Lumpur, Airlangga University, Chulalongkorn University, University of Szeged, National Taipei University and others. Learn more about the various benefits of D`OXYVA.
"There are a lot of possibilities here and we are really excited about conducting future studies to determine what D`OXYVA may be able to provide to people with microvascular disease."
- Prof. Judy M. Delp, Ph.D., Florida State University, U.S.A.
D`OXYVA is being recognized and touted by medical thought-leaders in the United States and many other countries as an upcoming industry-leading painless health technology that promises to change the dynamics of how health care is delivered at health care facilities and at home.
D`OXYVA is becoming highly advantageous for the patient, health care practitioner, and the entire healthcare system, and is starting to provide substantial cost savings and improvements in quality of life for a wide variety of health complications for people of all ages and backgrounds.
D`OXYVA is a CE-marked medical device (Class I, low risk). Circularity is seeking approvals via the U.S. FDA and in other countries for delivery of Medical Gases such as Medical Carbon Dioxide (USP UN1013) via a novel patented non-invasive transdermal route with D`OXYVA as treatment for various widespread conditions.
Medical Carbon Dioxide is manufactured and delivered under applicable standards per each country's regulatory requirements. In the United States, the Food and Drug Administration has cleared the use of Medical Carbon Dioxide for the route of inhalation for humans but not yet for transdermal delivery with D`OXYVA. Transportation of Medical Carbon Dioxide via any postal or courier service requires certification for handling Dangerous Goods (HAZMAT) by the U.S. Department of Transportation (DOT). Use of unapproved substances and products may be illegal, cause serious injury, and even death!
Warning! Ask your physician before using D`OXYVA FOR MEDICAL AND CLINICAL RESEARCH PURPOSES, prescription only. The D`OXYVA transdermal delivery device holds a growing number of Class I (low risk) medical device licenses around the world. Use for non-medical purposes is available over-the-counter (OTC) and in various retail stores online and offline. Circularity's novel D`OXYVA patented transdermal drug delivery pathway with FDA-cleared Medical Carbon Dioxide (UN1013) has not been evaluated yet by the U.S. Food and Drug Administration (FDA) and is not intended to diagnose, treat, cure, or prevent any disease. The information provided on this Website is for educational and research purposes and is not intended to replace medical advice. >Learn more